Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1507 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1507 | DRUG | 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients |
Inclusion Criteria: * female patients, \>=18 years of age; * invasive, and operable, breast cancer; * ECOG Performance Status of 0 or 1. Exclusion Criteria: * evidence of metastatic disease; * inflammatory breast cancer; * prior hormonal or systemic therapy for breast cancer; * prior treatment wi...
Top 20 of 92 competitors
RG1507 is an investigational small molecule being studied for the treatment of breast cancer and other neoplasms, or solid tumors. It has been evaluated in Phase 1 clinical trials in patients with advanced solid tumors, including a study specifically in women with operable breast cancer.
RG1507 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored multiple Phase 1 clinical trials of the drug in patients with advanced solid tumors and breast cancer.
RG1507 is in Phase 1 clinical development. It has completed two Phase 1 trials in adults and one Phase 1 trial in children and adolescents with advanced solid tumors. The drug is investigational and has not been approved by regulatory authorities.
RG1507 has been studied in three completed Phase 1 trials: NCT00400361, a multiple ascending dose study in adults with advanced solid tumors; NCT00560144, a similar study in children and adolescents; and NCT00882674, a study evaluating biological activity in women with operable breast cancer.
Yes, RG1507 is also known as R1507. The drug has been referred to by both names in clinical trial records, including studies NCT00400361, NCT00560144, and NCT00882674, which all use the R1507 designation.